The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
- PMID: 21194787
- DOI: 10.1016/j.ejcb.2010.11.005
The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential?
Abstract
Proteolytic ectodomain release, a process known as "shedding", has been recognised as a key mechanism for regulating the function of a diversity of cell surface proteins. A Disintegrin And Metalloproteinases (ADAMs) have emerged as the major proteinase family that mediates ectodomain shedding. Dysregulation of ectodomain shedding is associated with autoimmune and cardiovascular diseases, neurodegeneration, infection, inflammation and cancer. Therefore, ADAMs are increasingly regarded as attractive targets for novel therapies. ADAM10 and its close relative ADAM17 (TNF-alpha converting enzyme (TACE)) have been studied in particular in the context of ectodomain shedding and have been demonstrated as key molecules in most of the shedding events characterised to date. Whereas the level of expression of ADAM10 may be of importance in cancer and neurodegenerative disorders, ADAM17 mainly coordinates pro- and anti-inflammatory activities during immune response. Despite the high therapeutical potential of ADAM inhibition, all clinical trials using broad-spectrum metalloprotease inhibitors have failed so far. This review will cover the emerging roles of both ADAM10 and ADAM17 in the regulation of major physiological and developmental pathways and will discuss the suitability of specifically modulating the activities of both proteases as a feasible way to inhibit inflammatory states, cancer and neurodegeneration.
Copyright © 2010 Elsevier GmbH. All rights reserved.
Similar articles
-
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.Biochem J. 2008 Apr 15;411(2):433-9. doi: 10.1042/BJ20071430. Biochem J. 2008. PMID: 18215140
-
Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.Int J Cancer. 2013 Oct 1;133(7):1557-66. doi: 10.1002/ijc.28174. Epub 2013 Apr 18. Int J Cancer. 2013. PMID: 23526433
-
Identification of ADAM10 as a major TNF sheddase in ADAM17-deficient fibroblasts.Cytokine. 2009 Jun;46(3):309-15. doi: 10.1016/j.cyto.2009.03.002. Epub 2009 Apr 5. Cytokine. 2009. PMID: 19346138
-
The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer.Semin Cell Dev Biol. 2009 Apr;20(2):164-74. doi: 10.1016/j.semcdb.2008.09.005. Epub 2008 Sep 18. Semin Cell Dev Biol. 2009. PMID: 18951988 Review.
-
The Gut-Brain Axis in Autism Spectrum Disorder: A Focus on the Metalloproteases ADAM10 and ADAM17.Int J Mol Sci. 2020 Dec 24;22(1):118. doi: 10.3390/ijms22010118. Int J Mol Sci. 2020. PMID: 33374371 Free PMC article. Review.
Cited by
-
TspanC8 tetraspanins regulate ADAM10/Kuzbanian trafficking and promote Notch activation in flies and mammals.J Cell Biol. 2012 Oct 29;199(3):481-96. doi: 10.1083/jcb.201201133. Epub 2012 Oct 22. J Cell Biol. 2012. PMID: 23091066 Free PMC article.
-
Rhomboid family gene expression profiling in breast normal tissue and tumor samples.Tumour Biol. 2014 Feb;35(2):1451-8. doi: 10.1007/s13277-013-1199-8. Epub 2013 Nov 2. Tumour Biol. 2014. PMID: 24185965
-
Circadian rhythm and sleep-wake systems share the dynamic extracellular synaptic milieu.Neurobiol Sleep Circadian Rhythms. 2018 Apr 17;5:15-36. doi: 10.1016/j.nbscr.2018.04.001. eCollection 2018 Jun. Neurobiol Sleep Circadian Rhythms. 2018. PMID: 31236509 Free PMC article. Review.
-
The adherens junctions control susceptibility to Staphylococcus aureus α-toxin.Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14337-42. doi: 10.1073/pnas.1510265112. Epub 2015 Oct 21. Proc Natl Acad Sci U S A. 2015. PMID: 26489655 Free PMC article.
-
Expanding the Activity of Tissue Inhibitors of Metalloproteinase (TIMP)-1 against Surface-Anchored Metalloproteinases by the Replacement of Its C-Terminal Domain: Implications for Anti-Cancer Effects.PLoS One. 2015 Aug 26;10(8):e0136384. doi: 10.1371/journal.pone.0136384. eCollection 2015. PLoS One. 2015. PMID: 26308720 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous